CPT.one Biotech

CPT.one Biotech is a privately funded Danish biotech company, dedicated to the development of novel treatments primarily for patients suffering from secondary progressive multiple sclerosis (SP-MS). CPT-001 is partly in-licensed and further developed by CPT.one Biotech and has a first in class mode of action and block lipid transport in the mitochondria and thereby regulate fat and glucose metabolism. The target is mitochondrial CPT1 and the treatment reestablishes defectives in myelin sheets. CPT.one welcomes enquiries regarding partnering opportunities.